Immunotherapy and chemo combo before surgery for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have gallbladder cancer or bile duct cancer that has been confirmed by a biopsy.
- Your tumor can be surgically removed but is considered high-risk (e.g., larger than 5 cm, spread to nearby lymph nodes, or involving major blood vessels).
- You have not had any previous chemotherapy, radiation, or other systemic treatment for this cancer.
- Your overall health is good (ECOG score 0 or 1, meaning you can do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (adebrelimab), and a drug to boost white blood cells (mecapegfilgrastim) before surgery for people with biliary tract cancer. The goal is to see if this approach can shrink the tumor enough to make surgery possible.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (gemcitabine, cisplatin, S-1) given before surgery for patients with bile duct cancer that is high-risk for return or has come back within 6 months after a prior surgery. The goal is to see if this treatment can improve outcomes.
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
Hear when a new Biliary Tract Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.